Zdrowie i gospodarka · 01/04/2021

FDA Clears Way for Approval of SERENTIL Mesoridazine Besylate Tablets

The US Food and Drug Administration (FDA) has determined that SERENTIL mesoridazine besylate tablets in various strengths were not withdrawn from sale due to safety or effectiveness concerns. This decision enables the FDA to approve abbreviated new drug applications for these tablets if all applicable requirements are met.